169 related articles for article (PubMed ID: 26353589)
1. Co-Encapsulation of Combretastatin-A4 Phosphate and Doxorubicin in Polymersomes for Synergistic Therapy of Nasopharyngeal Epidermal Carcinoma.
Zhu J; Xu X; Hu M; Qiu L
J Biomed Nanotechnol; 2015 Jun; 11(6):997-1006. PubMed ID: 26353589
[TBL] [Abstract][Full Text] [Related]
2. Drug resistance reversal by combretastatin-A4 phosphate loaded with doxorubicin in polymersomes independent of angiogenesis effect.
Zhu J; Hu M; Qiu L
J Pharm Pharmacol; 2017 Jul; 69(7):844-855. PubMed ID: 28425588
[TBL] [Abstract][Full Text] [Related]
3. A co-delivery system based on paclitaxel grafted mPEG-b-PLG loaded with doxorubicin: preparation, in vitro and in vivo evaluation.
Li Q; Lv S; Tang Z; Liu M; Zhang D; Yang Y; Chen X
Int J Pharm; 2014 Aug; 471(1-2):412-20. PubMed ID: 24905776
[TBL] [Abstract][Full Text] [Related]
4. Galactose Modified Liposomes for Effective Co-Delivery of Doxorubicin and Combretastatin A4.
Lian B; Wei H; Pan R; Sun J; Zhang B; Wu J; Li X; Tian G
Int J Nanomedicine; 2021; 16():457-467. PubMed ID: 33488080
[TBL] [Abstract][Full Text] [Related]
5. Folate-targeted polymersomes loaded with both paclitaxel and doxorubicin for the combination chemotherapy of hepatocellular carcinoma.
Zhu D; Wu S; Hu C; Chen Z; Wang H; Fan F; Qin Y; Wang C; Sun H; Leng X; Kong D; Zhang L
Acta Biomater; 2017 Aug; 58():399-412. PubMed ID: 28627436
[TBL] [Abstract][Full Text] [Related]
6. Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model.
Yeung SC; She M; Yang H; Pan J; Sun L; Chaplin D
J Clin Endocrinol Metab; 2007 Aug; 92(8):2902-9. PubMed ID: 17550961
[TBL] [Abstract][Full Text] [Related]
7. Angiopep-2-conjugated poly(ethylene glycol)-
Lu F; Pang Z; Zhao J; Jin K; Li H; Pang Q; Zhang L; Pang Z
Int J Nanomedicine; 2017; 12():2117-2127. PubMed ID: 28356732
[TBL] [Abstract][Full Text] [Related]
8. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies.
Zhang YF; Wang JC; Bian DY; Zhang X; Zhang Q
Eur J Pharm Biopharm; 2010 Mar; 74(3):467-73. PubMed ID: 20064608
[TBL] [Abstract][Full Text] [Related]
9. Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors.
Dziba JM; Marcinek R; Venkataraman G; Robinson JA; Ain KB
Thyroid; 2002 Dec; 12(12):1063-70. PubMed ID: 12593719
[TBL] [Abstract][Full Text] [Related]
10. Synergistic breast tumor cell killing achieved by intracellular co-delivery of doxorubicin and disulfiram via core-shell-corona nanoparticles.
Tao X; Gou J; Zhang Q; Tan X; Ren T; Yao Q; Tian B; Kou L; Zhang L; Tang X
Biomater Sci; 2018 Jun; 6(7):1869-1881. PubMed ID: 29808221
[TBL] [Abstract][Full Text] [Related]
11. Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma.
Nelkin BD; Ball DW
Oncol Rep; 2001; 8(1):157-60. PubMed ID: 11115589
[TBL] [Abstract][Full Text] [Related]
12. Water-Soluble Combretastatin A4 Phosphate Orally Delivered via Composite Nanoparticles With Improved Inhibition Effect Toward S180 Tumors.
Shen Y; Wu L; Qiu L
J Pharm Sci; 2017 Oct; 106(10):3076-3083. PubMed ID: 28619603
[TBL] [Abstract][Full Text] [Related]
13. Combretastatin-A4 phosphate improves the distribution and antitumor efficacy of albumin-bound paclitaxel in W256 breast carcinoma model.
Gao M; Zhang D; Jin Q; Jiang C; Wang C; Li J; Peng F; Huang D; Zhang J; Song S
Oncotarget; 2016 Sep; 7(36):58133-58141. PubMed ID: 27531898
[TBL] [Abstract][Full Text] [Related]
14. Hepatocellular Carcinoma: Intra-arterial Delivery of Doxorubicin-loaded Hollow Gold Nanospheres for Photothermal Ablation-Chemoembolization Therapy in Rats.
Li J; Zhou M; Liu F; Xiong C; Wang W; Cao Q; Wen X; Robertson JD; Ji X; Wang YA; Gupta S; Li C
Radiology; 2016 Nov; 281(2):427-435. PubMed ID: 27347765
[TBL] [Abstract][Full Text] [Related]
15. EGFR-targeted multifunctional polymersomal doxorubicin induces selective and potent suppression of orthotopic human liver cancer in vivo.
Fang Y; Yang W; Cheng L; Meng F; Zhang J; Zhong Z
Acta Biomater; 2017 Dec; 64():323-333. PubMed ID: 29030307
[TBL] [Abstract][Full Text] [Related]
16. Glycyrrhetinic acid-conjugated polymeric prodrug micelles co-delivered with doxorubicin as combination therapy treatment for liver cancer.
Yang T; Lan Y; Cao M; Ma X; Cao A; Sun Y; Yang J; Li L; Liu Y
Colloids Surf B Biointerfaces; 2019 Mar; 175():106-115. PubMed ID: 30529816
[TBL] [Abstract][Full Text] [Related]
17. Nanogel-Incorporated Injectable Hydrogel for Synergistic Therapy Based on Sequential Local Delivery of Combretastatin-A4 Phosphate (CA4P) and Doxorubicin (DOX).
Yang WJ; Zhou P; Liang L; Cao Y; Qiao J; Li X; Teng Z; Wang L
ACS Appl Mater Interfaces; 2018 Jun; 10(22):18560-18573. PubMed ID: 29767951
[TBL] [Abstract][Full Text] [Related]
18. Targeted delivery of a combination therapy consisting of combretastatin A4 and low-dose doxorubicin against tumor neovasculature.
Yang T; Wang Y; Li Z; Dai W; Yin J; Liang L; Ying X; Zhou S; Wang J; Zhang X; Zhang Q
Nanomedicine; 2012 Jan; 8(1):81-92. PubMed ID: 21664295
[TBL] [Abstract][Full Text] [Related]
19. Robust, tumor-homing and redox-sensitive polymersomal doxorubicin: A superior alternative to Doxil and Caelyx?
Zou Y; Meng F; Deng C; Zhong Z
J Control Release; 2016 Oct; 239():149-58. PubMed ID: 27569664
[TBL] [Abstract][Full Text] [Related]
20. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
